Literature DB >> 29037065

Patterns of symptom development in patients with motor neuron disease.

Renée Walhout1, Esther Verstraete1, Martijn P van den Heuvel2, Jan H Veldink1, Leonard H van den Berg1.   

Abstract

OBJECTIVE: To investigate whether symptom development in motor neuron disease (MND) is a random or organized process.
METHODS: Six hundred patients with amyotrophic lateral sclerosis (ALS), upper motor neuron (UMN) or lower motor neuron (LMN) phenotypes were invited for a questionnaire concerning symptom development. A binomial test was used to examine distribution of symptoms from site of onset. Development of symptoms over time was evaluated by Kaplan-Meier analysis.
RESULTS: There were 470 respondents (ALS = 254; LMN = 100; UMN = 116). Subsequent symptoms were more often in the contralateral limb following unilateral limb onset (ALS: arms p = 1.05 × 10-8, legs p < 2.86 × 10-15; LMN phenotype: arms p = 6.74 × 10-9, legs p = 6.26 × 10-6; UMN phenotype: legs p = 4.07 × 10-14). In patients with limb onset, symptoms occurred significantly faster in the contralateral limb, followed by the other limbs and lastly by the bulbar region. Patterns of non-contiguous symptom development were also reported: leg symptoms followed bulbar onset in 30%, and bulbar symptoms followed leg onset in 11% of ALS patients.
CONCLUSIONS: Preferred spread of symptoms from one limb to the contralateral limb, and to adjacent sites appears to be a characteristic of MND phenotypes, suggesting that symptom spread is organized, possibly involving axonal connectivity. Non-contiguous symptom development, however, is not uncommon, and may involve other factors.

Entities:  

Keywords:  Motor neuron disease; amyotrophic lateral sclerosis; lower motor neuron; symptom development; upper motor neuron

Mesh:

Year:  2017        PMID: 29037065     DOI: 10.1080/21678421.2017.1386688

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  12 in total

1.  The Prevalence and Management of Saliva Problems in Motor Neuron Disease: A 4-Year Analysis of the Scottish Motor Neuron Disease Register.

Authors:  Iona Pearson; Stella A Glasmacher; Judith Newton; Emily Beswick; Arpan R Mehta; Richard Davenport; Siddharthan Chandran; Suvankar Pal
Journal:  Neurodegener Dis       Date:  2021-04-26       Impact factor: 2.977

2.  Optimizing the Translational Value of Mouse Models of ALS for Dysphagia Therapeutic Discovery.

Authors:  Kate L Osman; Sabrina Kohlberg; Alexis Mok; Ryan Brooks; Lori A Lind; Katelyn McCormack; Andries Ferreira; Matan Kadosh; Mary K Fagan; Elizabeth Bearce; Nicole L Nichols; Joan R Coates; Teresa E Lever
Journal:  Dysphagia       Date:  2019-07-12       Impact factor: 3.438

3.  Functional alterations in large-scale resting-state networks of amyotrophic lateral sclerosis: A multi-site study across Canada and the United States.

Authors:  Komal Bharti; Simon J Graham; Michael Benatar; Hannah Briemberg; Sneha Chenji; Nicolas Dupré; Annie Dionne; Richard Frayne; Angela Genge; Lawrence Korngut; Collin Luk; Lorne Zinman; Sanjay Kalra
Journal:  PLoS One       Date:  2022-06-16       Impact factor: 3.752

4.  Spreading in ALS: The relative impact of upper and lower motor neuron involvement.

Authors:  Marta Gromicho; Manuel Figueiral; Hilmi Uysal; Julian Grosskreutz; Magdalena Kuzma-Kozakiewicz; Susana Pinto; Susanne Petri; Sara Madeira; Michael Swash; Mamede de Carvalho
Journal:  Ann Clin Transl Neurol       Date:  2020-06-18       Impact factor: 4.511

5.  Wild-type Cu/Zn-superoxide dismutase is misfolded in cerebrospinal fluid of sporadic amyotrophic lateral sclerosis.

Authors:  Eiichi Tokuda; Yo-Ichi Takei; Shinji Ohara; Noriko Fujiwara; Isao Hozumi; Yoshiaki Furukawa
Journal:  Mol Neurodegener       Date:  2019-11-19       Impact factor: 14.195

6.  Prion-Like Propagation of Protein Misfolding and Aggregation in Amyotrophic Lateral Sclerosis.

Authors:  Luke McAlary; Steven S Plotkin; Justin J Yerbury; Neil R Cashman
Journal:  Front Mol Neurosci       Date:  2019-11-01       Impact factor: 5.639

7.  Cortical inexcitability defines an adverse clinical profile in amyotrophic lateral sclerosis.

Authors:  T Dharmadasa; J Howells; J M Matamala; N G Simon; D Burke; S Vucic; M C Kiernan
Journal:  Eur J Neurol       Date:  2020-10-09       Impact factor: 6.089

8.  Progressive arm muscle weakness in ALS follows the same sequence regardless of onset site: use of TOMS, a novel analytic method to track limb strength.

Authors:  Nimish J Thakore; Brian J Drawert; Brittany R Lapin; Erik P Pioro
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2021-02-23       Impact factor: 3.528

9.  The rostral to caudal gradient of clinical and electrophysiological features in sporadic amyotrophic lateral sclerosis with bulbar-onset.

Authors:  Song-Jie Liao; Zi Huang; Chong-Yuan Lai; Jing-Yan Chen; Pei-Yao Xiao; Qiong Cai; Jian Yu
Journal:  J Int Med Res       Date:  2020-09       Impact factor: 1.671

10.  Evaluation of Amyotrophic Lateral Sclerosis-Induced Muscle Degeneration Using Magnetic Resonance-Based Relaxivity Contrast Imaging (RCI).

Authors:  Sudarshan Ragunathan; Laura C Bell; Natenael Semmineh; Ashley M Stokes; Jeremy M Shefner; Robert Bowser; Shafeeq Ladha; C Chad Quarles
Journal:  Tomography       Date:  2021-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.